echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Retin Pharmaceuticals "Toluene Omarcycline" listing application to be included in the priority review

    Retin Pharmaceuticals "Toluene Omarcycline" listing application to be included in the priority review

    • Last Update: 2020-05-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Developed by Paratek Pharmaceuticals, a pharmaceutical partner, toluene is a new type of tetracycline designed to overcome tetracycline resistance and has broad-spectrum antibacterial activity, including gramobacteria, gram-negative bacteria, atypical pathogens and a variety of drug-resistant strainsthe drug was available in the U.Sin February 2019 as a daily oral and intravenous antibiotic for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infection (ABSSSI), known as NuzyraDrHarald Reinhart, Chief Medical Officer, Autoimmune and Anti-Infection,, said: "Toluene Omarcycline has broad-spectrum antibacterial activity and is highly active against drug-resistant strains, making it suitable for treatment in patients with CABP and ABSSSI in ChinaWith both intravenous infusion and oral prosdors, toluene omarlygcane can provide intravenous-oral sequence treatment options that can help patients significantly reduce the number of days in hospital and reduce the risk of infection in the hospitalAt present, China has limited treatment options for drug-resistant strains, and toluene omarlycin, as an innovative antibiotic drug, can address such unmet medical needs"
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.